Arecae Semen Tostum Veterinary Grade API is supplied as a processed botanical active pharmaceutical ingredient derived from the roasted seeds of Areca catechu L., and is specified separately from raw Arecae Semen powder and synthetic arecoline salts. The product is differentiated by particle-size distribution, bulk density, residual moisture, bioburden class, and endotoxin burden to match the manufacturing demands of tablets, hard capsules, oral powders, granules, premixes, injectable solutions, and liquid oral solutions. Representative model designations for veterinary formulation include a micronized oral grade with D90 ≤ 75 µm for suspension and low-shear mixing processes, a granular direct-compression grade with D50 120–250 µm and angle of repose ≤ 35°, and a reduced-endotoxin parenteral-grade extract standardized to arecoline content. The active marker is arecoline, with arecaidine and guvacine present as secondary alkaloids; the tostum process reduces the extractable condensed tannin fraction and lowers the concentration of free polyphenols compared with untreated seed. Residual moisture is controlled to ≤ 8.0% for oral grades and ≤ 5.0% for the parenteral-grade extract. Release testing includes chromatographic identity, total alkaloid assay expressed as arecoline, microbial limits, heavy metal screening, and residual solvent testing aligned with ICH Q3C. The material is handled in facilities with controlled relative humidity ≤ 45% RH during dispensing and bag loading to prevent caking and moisture uptake.

For tablets and hard capsules, the toasted botanical matrix differs from synthetic arecoline hydrobromide in its compressibility, dissolution, and assay strategy. Synthetic salt can be assayed as a single-molecule API, whereas the botanical product requires a chromatographic fingerprint and total alkaloid assay. Tablet formulations typically combine the granular oral grade with microcrystalline cellulose and croscarmellose sodium; final blend moisture is held below 3.0% before compression to prevent capping and picking on the tablet tooling. Hardness targets are commonly 50–80 N for tablets intended for canine or equine administration, but the acceptable range depends on tablet shape, embossing, and disintegration requirement. Disintegration is evaluated using Ph. Eur. 2.9.1; tablets containing toasted botanical API should disintegrate within 15 min in water at 37 °C when immediate release is specified.

Why Does Tostum Processing Alter the Alkaloid Release Profile Relative to Raw Seed Powder?

Raw Arecae Semen contains proanthocyanidins and condensed tannins that bind to alkaloids and dietary proteins, retard arecoline dissolution, and contribute to astringency. During tostum processing, the seed is exposed to controlled moist-heat or dry-heat treatment followed by rapid cooling and size reduction; oxidative polymerization during the heating step reduces the extractable tannin fraction while alkaloid retention depends on thermal load and seed moisture. The analytical consequence is a shift in in vitro release under acidic dissolution media, with toasted API typically yielding faster initial arecoline liberation in the pH range 1.2–4.0, whereas raw seed powder can exhibit slower and more variable release due to tannin-alkaloid complexation. This difference is quantified using HPLC assay of arecoline and arecaidine before and after Ph. Eur. 2.9.3 dissolution testing; pharmaceutical batches are standardized by alkaloid content rather than total extractive weight, which reduces variability in dose per animal bodyweight. Compared with synthetic arecoline hydrobromide, the botanical API contains guvacine and arecaidine as secondary alkaloids; the exact ratio varies by harvest and tostum lot, so batch-specific chromatographic fingerprint data are required for release. Compared with raw seed powder, the toasted material also shows lower residual moisture and a reduced initial aerobic microbial count because of the thermal processing step.

Analytical control for the toasted botanical matrix follows herbal drug principles rather than single-molecule API protocols. The assay is performed by acid-base extraction into an organic solvent, followed by reversed-phase HPLC with UV detection; system suitability requires a resolution of at least 2.0 between arecoline and arecaidine peaks. Because the ratio of arecaidine to arecoline can shift with storage temperature and moisture, the specification includes a chromatographic purity limit and a maximum arecaidine content for parenteral grades. Method validation follows ICH Q2(R1) for specificity, linearity, accuracy, and precision. Published data for the absolute alkaloid ratio in toasted Arecae Semen from different geographic origins is limited; therefore, incoming lots are quarantined until the batch-specific fingerprint is evaluated against the approved reference chromatogram.

Injectable solution manufacturing with Arecae Semen Tostum API places the greatest stress on alkaloid stability and sterility assurance. The water-soluble fraction is obtained by aqueous extraction at pH 3.5–4.5, because arecoline is an ester alkaloid with maximum hydrolytic stability in mildly acidic solution and degrades to arecaidine as pH rises above 6.5. Extraction and compounding vessels are specified as 316L stainless steel with electropolished surfaces to minimize metal-ion-catalyzed degradation of the ester bond. The solution is clarified by depth filtration followed by membrane filtration through a 0.45 µm prefilter and a 0.22 µm final PES membrane. Terminal steam sterilization at 121 °C for 15 min is not generally recommended without a thermal degradation study because arecoline hydrolysis can exceed the allowable assay range; aseptic filtration with pre-sterilized capsule filters is therefore used for heat-sensitive injectable preparations. Bacterial endotoxin limits for the parenteral-grade extract are set at ≤ 0.5 EU/mg. For large-volume parenterals, the pH is held between 3.0 and 4.0 with citrate or acetate buffer, and oxygen is displaced by nitrogen sparging to reduce oxidative discoloration from residual polyphenols. The material is incompatible with alkaline excipients such as full-strength disodium hydrogen phosphate buffers and with strong oxidizing agents. Residual tannins may precipitate when pH is adjusted above 6.0, requiring re-filtration validation if neutral pH is unavoidable. Published data for long-term stability of this specific botanical configuration in injectable formulation is limited; therefore, ICH Q1A bracketing and matrixing studies are required when assigning retest dates.

Parenteral-grade extract is produced by low-temperature vacuum concentration of the acidified aqueous extract, followed by lyophilization or spray-drying with a pharmaceutically acceptable carrier. The spray-dried material is hygroscopic and is packed under nitrogen to limit moisture uptake. In-process bioburden before final filtration is monitored; a limit of ≤ 10 CFU/100 mL is applied before the prefiltration step. Filter integrity tests are conducted with bubble point or diffusive flow, and the filling area uses an ISO Class 5 critical zone with an ISO Class 7 background per ISO 14644-1:2015. Compatibility testing with sodium chloride and mannitol as tonicity modifiers is required; no precipitation is observed at pH 3.5–4.5, but published data for all tonicity modifiers in this specific configuration is limited.

When Direct Compression Requires Granulated Intermediate Grades

Direct-compression tablet and capsule manufacturing of toasted botanical API is constrained by particle-size distribution, hygroscopicity, and flow. The granular oral grade with D50 120–250 µm and bulk density 0.55–0.75 g/mL is suitable for gravity-fed rotary tablet presses at press speeds up to 30 rpm, but high-speed presses above 60 rpm may require forced feeders and external lubrication because residual seed oil and fibrous material increase die-fill variability. For capsule filling, the same grade is processed through dosator machines with pin settings validated against fill weight RSD ≤ 3.0%. Where direct compression is not feasible, a wet-granulation route is selected using an aqueous binder; however, the drying step must avoid inlet air temperatures above 60 °C for fluid-bed dryers and product temperatures above 45 °C for tray dryers, because arecoline loss accelerates with free moisture and heat. In a production-scale fluid-bed configuration with a 120 kg batch size and 60 min drying time, maintaining the product bed at 40–45 °C limited alkaloid loss to ≤ 2.5% relative to the granulation feed; however, published data for this specific configuration is limited. The granulated intermediate is milled through an oscillating granulator with a 1.0 mm screen for tablets or a 1.25 mm screen for premix. Magnesium stearate is limited to ≤ 1.0% w/w because higher levels delay dissolution of the botanical matrix under simulated gastric conditions.

Specification and Compliance Matrix for Multidose Premix Applications

Premix and oral powder formulations require tighter particle-size control than tinctures or unprocessed powders because low-dose distribution in feed depends on blend uniformity. The granular premix grade is typically diluted with calcium carbonate or rice hulls to a final arecoline concentration of 0.05–0.20% w/w before addition to feed, and the final feed is assayed because arecoline distribution in pelleted feed depends on conditioning temperature, moisture, and post-pellet cooling. The table below summarizes the specification matrix used when qualifying animal health premises.

Differences from non-pharmacopoeial raw powders become measurable in premix uniformity. Raw seed powder with a wide particle-size distribution can segregate in a horizontal ribbon blender, while the toasted API’s controlled sieve cut and lower surface oil reduce minimum blend time to 10 min in a 500 kg capacity double-ribbon blender. Mix uniformity is tested by sampling 10 points and assaying arecoline with RSD ≤ 5.0%; the same batch using raw powder may require 20–25 min and still exceed RSD limits in low-dose premixes. High mineral diets containing alkaline calcium sources can increase local pH at particle surfaces and reduce arecoline recovery after pelleting; therefore, acidifiers such as citric acid at 0.5–1.0% w/w are sometimes included to stabilize the alkaloid during conditioning. The final feed is assayed after 24 h of storage and, where required, after 30 days under 25 °C/60% RH in closed multilayer bags. Published data for long-term carryover in feed milling equipment is limited, and flush material must be tested before releasing subsequent non-medicated batches.

Production-scale handling of the toasted API requires dust control and segregation because the milled material contains fibrous seed particles with poor wetting behavior. Single-use polyethylene liners inside fiber drums are used for oral grades, while the parenteral-grade extract is packed in aluminum-laminated bags with desiccant and oxygen absorber. Incoming material is sampled according to ISO 2859-1:2017, AQL 1.0 for identity and assay, and retained samples are stored under 20–25 °C and ≤ 40% RH. Equipment cleaning after processing requires an acidic aqueous solution at pH 2.5–3.5 to dissolve arecoline salts, followed by 70% isopropanol rinse; water alone leaves visible residual film on contact surfaces. Swab limits are validated by HPLC with a quantification limit of ≤ 1 µg/100 cm². Because areca nut has been classified by IARC Monographs Volume 85 as carcinogenic to humans when chewed as betel quid, closed-system handling and exposure controls are mandatory during milling, sampling, and packing. The API is restricted to veterinary drug manufacturing under current good manufacturing practice; use in food-producing species requires residue depletion data and regulatory approval because arecoline is a cholinergic agonist and overdosage can produce cholinergic crisis in target animals. Concurrent administration with other cholinergic agents is contraindicated in target animals because additive muscarinic effects can produce bronchoconstriction and bradycardia. The product must be stored in sealed containers below 25 °C and protected from light; exposure to high humidity above 60% RH causes caking and increases the risk of mold growth in oral grades. Incompatibilities include alkaline granulating agents, strong oxidizing disinfectants used in adjacent equipment cleaning, and direct contact with uncoated carbon steel surfaces, which can promote visible discoloration and alkaloid loss. Published data for long-term stability in all dosage forms is limited; therefore, formal stability programs under ICH Q1A conditions are required for each finished product configuration.